Number of qualified patients: CDEC discussed the uncertainty in the quantity of people with reasonably significant to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Clinical industry experts consulted by CADTH indicated that some individuals who're labeled as having mild or moderate condition could have a critical bleeding phenotype, https://hemgenix49381.win-blog.com/16451493/not-known-factual-statements-about-hemgenix